Recent 8-K filings for MAIA
Highest-materiality recent filing
MAIA reports OS >2 years for 8 NSCLC patients; 1 at 33 months in 3L
- Eight patients treated with ateganosine + cemiplimab in Phase 2 THIO-101 trial had overall survival exceeding 24 months.
- One 3rd-line patient survived 33 months vs. expected 5.8 months; four 2nd-line patients survived >30 months vs. SOC 10.5 months.
-
MAIA activates first U.S. site for Phase 2 THIO-101 trial in advanced NSCLC
First U.S. site activated at Summit Medical Group (NJ); four more U.S. sites planned in 2026.
-
MAIA Biotechnology: $33M raise fully funds pivotal Phase 3 trial for ateganosine in NSCLC
Net proceeds from $33M March 2026 common stock offering expected to fully fund pivotal Phase 3 trial (THIO-104) for ateganosine in third-line NSCLC.
-
MAIA reports OS >2 years for 8 NSCLC patients; 1 at 33 months in 3L
Eight patients treated with ateganosine + cemiplimab in Phase 2 THIO-101 trial had overall survival exceeding 24 months.
-
MAIA presents THIO-101 data at ELCC showing sustained response in relapsed NSCLC
Poster presented at European Lung Cancer Congress 2026 in Copenhagen on March 27, 2026.
-
MAIA Biotechnology closes $30M public offering of 20M shares at $1.50/sh
Closed underwritten public offering of 20M shares at $1.50/sh, gross proceeds $30M.
-
MAIA Biotechnology updates on Phase 3 ateganosine trial in NSCLC; Fast Track status
Ongoing Phase 3 full approval trial of ateganosine for third-line non-small cell lung cancer.
-
MAIA Biotechnology updates ateganosine program, targeting early commercial approval in NSCLC
Ateganosine obtained FDA Fast Track designation for NSCLC in 2025; company expects potential Accelerated Approval and Priority Review.
-
MAIA Biotechnology announces $1.51M private placement of common stock and warrants
Gross proceeds ~$1.51M from 1,233,488 shares at $1.224 each, with warrants exercisable at $1.36.
-
MAIA dosed first patient in THIO-104 Phase 3 trial of ateganosine for third-line NSCLC
First patient dosed in THIO-104 Phase 3 pivotal trial evaluating ateganosine + CPI vs chemo in third-line NSCLC.
-
MAIA touts $50B immunotherapy market; ateganosine gets Fast Track for NSCLC, Phase 3 starting
FDA Fast Track Designation for ateganosine in NSCLC patients resistant to immunotherapy and chemotherapy.
-
12 patients enrolled to date in Phase 2 THIO-101 expansion trial; sites now open in EMA countries, Turkey, and Taiwan.
-
MAIA reports 30-month (912-day) survival for a Phase 2 NSCLC patient; ESMO posters presented
One third-line NSCLC patient on ateganosine (THIO) survived 30 months/912 days as of Sep 17, 2025.
-
MAIA Biotechnology to hold up to 90% of liquid assets in Bitcoin, Ethereum, and USDC
Board authorized up to 90% of liquid assets to be held in cryptocurrencies: BTC, ETH, and USDC.
-
MAIA Biotechnology announces $2.25M private placement of stock and warrants
Gross proceeds ~$2.25M from sale of 1,733,766 shares at $1.30; one warrant per share at $1.57 exercise price.
-
MAIA Biotechnology awarded $2.3M NIH grant for THIO-101 Phase 2 trial in NSCLC
NIH grant of $2.3M supports expansion of THIO-101 Phase 2 trial evaluating ateganosine as third-line NSCLC treatment.
-
MAIA reports positive THIO-101 Phase 2 data: PFS 5.6 mo, OS 17.8 mo in 3L NSCLC
Estimated median PFS of 5.6 months (180 mg dose) vs 2.5 months standard of care in third-line NSCLC.
-
European Patent Office grants patent for ateganosine-based analogues for telomere-targeting anticancer therapy.
-
MAIA Biotech gets FDA Fast Track for ateganosine in NSCLC; Phase 2 data shows 17.8-month median OS
FDA granted Fast Track designation for ateganosine (THIO) for treatment of non-small cell lung cancer.
-
First patient dosed in Taiwan in THIO-101 expansion for 3L NSCLC after CPI/chemo failure.
-
Total purchase amount up to $587,905; monthly payments equal to 33% of invoices for Phase 3 THIO trial services provided by Prevail affiliate InfoWorks.
-
MAIA signs master clinical supply agreement with Roche for ateganosine-atezolizumab combo studies
Agreement supports future studies combining MAIA's ateganosine (THIO) with Roche's atezolizumab (Tecentriq) for multiple hard-to-treat cancers.
-
MAIA reports 17.8-month median OS in NSCLC trial; new partial response after 20 months
Median overall survival of 17.8 months for 22 third-line NSCLC patients, nearly triple the 5-6 month SOC.
-
MAIA presents Phase 2 THIO-101 NSCLC efficacy data at ASCO 2025
Poster presented at 2025 ASCO Annual Meeting on May 31 showing efficacy from Phase 2 THIO-101 trial.
-
MAIA Biotechnology details 2025 clinical milestones; potential FDA filings in 2026 for THIO
Lead compound THIO is the only clinical-stage telomere-targeting anticancer agent.
-
MAIA presents Phase 2 THIO-101 efficacy data in advanced NSCLC at ELCC 2025
Efficacy data from Phase 2 THIO-101 trial presented at European Lung Cancer Congress 2025 on March 28, 2025.
-
MAIA plans Phase 3 pivotal trial of THIO+CPI vs chemo in NSCLC patients
Phase 3 trial THIO-104 to enroll up to 300 patients with third-line NSCLC.
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material